medigraphic.com
ISSN 1561-3070 (Electronic)

2016, Number 2

<< Back Next >>

Rev Cub Oftal 2016; 29 (2)

Uses of botulinum toxin in eyelid diseases

Rojas-Rondón I, Llamas-Meriño J, Ramírez-García L, Gómez-Cabrera C, Rodríguez SG, Álvarez MN

Language: Spanish
References: 43
Page: 316-331
PDF size: 230.88 Kb.


ABSTRACT

Botulinum toxin is a highly specific potent neuromuscular inhibitor that produces a chemical denervation when blocking the release of acetylcholine in the motor plaque. It is synthesized by Clostridium botulinum. It is a drug with high therapeutic value to treat ocular adnexas and may be indicated for primary blepharospasm, hemifacial spasm, chalazion, spasmodic entropion, palpebral retraction, eye brow ptosis, palpebral myokymia and in treating expression lines of the face, all with very good esthetic results. Literature search was made in Internet by using databases such as Medline, Google, Bireme, PubMed.gov, as well as outstanding articles of the American Academy of Ophthalmology and Neurology with the objective of describing the uses of botulinum toxin for ocular adnexa diseases.


REFERENCES

  1. De Maio M, Ofenböck I, Narvaes C. Toxina botulínica: relación entre tipo de paciente y duración del efecto. Cir Plást Iberolatinoam. 2008;34(1):19-24.

  2. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol. 2009;16:392-8.

  3. Carruthers A, Carruthers J. Eyebrow height after botulinum toxin type A to the glabellar. Dermatol Surg. 2007;33(Suppl.):26-31.

  4. Brin MF. Basic and clinical aspects of BOTOX. Toxicon. 2009;54:676-82.

  5. Garg A, Nassaralla BA, El-Toukhy E, Kaynak-Hekimhan P, Moreker S. Surgical and Medical Management of Pterygium. India: Jaypee Brothers Medical Publishers; 2009. p. 544-70.

  6. Martínez GG, Álvarez LA. Toxina Botulínica. En: Toledano FN, Martínez GG, Prada SC, Sanz LA, Mendel JR, Blanco MG. Cirugía palpebral y periocular; 2009. p. 373-408.

  7. Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Doubleblind study of botulinum toxin in spasmodic torticolis. Lancet. 1986;2:245-7.

  8. Jankovic J, Shwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spsmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53:633-9.

  9. Kranz G, Haubenberger D, Voller B, Psoch M, Schnider P, Auff E, Sycha T. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord. 2009;24:231-6.

  10. Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol. 2008;7:50-4.

  11. Albert MD, Miller WJ, Azar TD, Blondi AB. Albert and Jakobiec's Principles and Practice of Ophthalmology. Philadelphia: Saunders Elsevier; 2008;2. p. 2135-40.

  12. Alonso-Navarro H, Jiménez-Jiménez FJ, Plaza-Nieto JF, Pilo-de la Fuente B, Navacerrada F, Arroyo-Solera M, et al. Treatment of severe bruxism with botulinum toxin type A. Rev Neurol. 2011;53:73-6.

  13. Kranz G, Haubenberger D, Voller B, Psoch M, Schnider P, Auff E, et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord. 2009;24:231-6.

  14. Lluis GC, Hernández MG. La toxina botulínica: de enemigo a aliado. Actualid Farmacol Terap. 2008;6(2):105-10.

  15. Casado Sánchez C, Martínez Méndez JR. Disección anatómica de la musculatura mímica facial: revisión iconográfica de apoyo a los tratamientos complementarios en rejuvenecimiento facial. Madrid: Cir Plást Iberolatinoamer. 2011;7(1):91-7.

  16. Alcolea JM. Actualización sobre aplicaciones de la toxina botulínica es estética facial. Madrid: Cir Plást Iberolatinoam. 2011;37(1):81-3.

  17. Wenzel R, Jones D, Borrego A. Comparing two botulinum toxin type A formulations using manufacturers product summaries. J Clin Pharm Ther. 2007;32:387-402.

  18. Mukai Y, Kaji R. Use of botulinum neurotoxin therapy. Brain Nerve. 2011;63:775-84.

  19. Jewell ML, Monheit GD. An overview of clinical trial data on a new formulation of botulinum neurotoxin type A. Aesthet Surg J. 2009;29(Suppl.):31-3.

  20. Monheit G, Cohen J, Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol. 2009;61:421-5.

  21. Tsai CP, Chiu MC, Yen DJ, Guo YC, Y CL, Lee TC. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of Idiopathic blepharospasm and hemifacial spasm. Acta Neurol Taiwan. 2005;14:61-8.

  22. Pikett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol. 2009;61:149-50.

  23. Klein AW. Dilution and storage of Botulinum Toxin. Dermatologic Surg. 1998;11(24):1179-87.

  24. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebocontrolled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surg. 2007;33(1):51.

  25. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41:1088-91.

  26. Fahn S, Marsden CD, Calne DB. Dystonia: advances in neurology. New York: Raven Press; 2009.

  27. Faucett DC. Essential blepharospasm. In: Yanoff M, Duker JS, eds. Ophthalmology. St. Louis: Mosby Elsevier; 2008. p. 43.

  28. Yanoff M, Cameron D. Diseases of the visual system. In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011. p. 86.

  29. Echeverría-Urabayen A, Fanjul S, Meseguer E, García-Ruiz Espiga PJ. Evolución de la dosis de toxina botulínica tipo A en distonías craneocervicales. Estudio comparativo a lo largo de ocho años. Rev Neurol. 2004;38:511-3.

  30. Hsiung GYR, Das SK, Ranawaya BM, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10- year period. Mov Disord. 2002;17:1288-93.

  31. Winterhoff J, Köhler S, Laskawi R. Botulinumtoxintherapie beim spastischen Entropium. HNO. 2013;61(7):665-7.

  32. Amarendra Deka SP, Saikia S. Botulinum toxin for lower lid entropion correction. India: Bawri Nethralaya. 2011;30(1):40-2.

  33. Alcolea JM. Actualización sobre aplicaciones de la toxina botulínica es estética facial. Cir Plást Iberolatinoam. 2011;7(1):81-3.

  34. Bartalena L, Tanda M. Graves' Ophthalmopathy. N Engl J Méd. 2009;360:994-1001.

  35. Sasim IV, Berendschot TT, van Isterdael C, Mourits MP. Planning health care for patients with Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2008;1315-21.

  36. Costa PG, Saraiva FP, Pereira IC, Monteiro MLR, Matayoshi S. Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye. 2008:165-7.

  37. Goldberg RA. Advances in surgical rehabilitation in thyroid eye disease. Thyroid. 2008;18(9):989-95.

  38. Cáceres TM, Márquez FM, Cáceres TO. Toxina botulínica "A" versus cirugía en la retracción palpebral de la orbitopatía tiroidea. Rev Cubana Oftalmol. 2011;23(2):241-8.

  39. Ellis MF, Daniell M. An evaluation of the safety and efficacy of botulinum toxin type A (Botox) when used to produce a protective ptosis. Clin Exp Ophthalmol. 2001;29:394-9.

  40. Flores M, Trelles MA. La técnica Face-up: lifting facial mini invasivo con hilos tensores". Cir Plást Iberolatinoam. 2008;34(1):27-39.

  41. Trelles MA. Nuevas tecnologías en cirugía plástica-estética. Madrid: Cir Plást Iberolatinoam. 2012;38(3):15-8.

  42. Sánchez FAV, Miquenes VX. Carta al director. Estrabismo y toxina botulínica. Arch Soc Esp Oftalmol. 2013;88(7):286-7.

  43. Monheit G, Cohen J; Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol. 2009;61:421-5.




2020     |     www.medigraphic.com